Retrieved from Aparicio E, Jard C, Bedmar C, et al
Increasing attention has been directed toward the concept of a therapeutic window of opportunity, which frames early PsA as a transitional phase characterized by musculoskeletal symptoms such as arthralgia, dactylitis, and subclinical enthesitis in patients with PsO, often preceding clinically evident arthritis ( These considerations highlight the need for future studies specifically designed to evaluate GLP-1RAs in patients at high risk of PsA, particularly those with subclinical inflammation or early musculoskeletal symptoms
If you're starting semaglutide therapy at PlexusDx and have a history of constipation or irritable bowel syndrome, mention this upfront so your provider can counsel you on prevention before constipation becomes a barrier to treatment adherence
How Much Protein Do You Need on a GLP-1
Individual calorie requirements on GLP-1 therapy depend on numerous physiological and lifestyle factors that must be considered for personalised nutritional planning
Key Takeaways: Full Framework A drug patents value is the sum of legally defensible exclusivity, multiplied by commercially addressable revenue, discounted by development risk, adjusted for competitive erosion, litigation costs, and post-LOE revenue trajectory